Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Panza

Showing results (31-40 of 404) with videos related to

Pageof 41
Sort By:
Expert Opinion on Emerging Drugs|March 21, 2025
An update on emerging anti-amyloid-β monoclonal antibodies for treating Alzheimer's disease: the role of apolipoprotein EMadia Lozupone, Vittorio Dibello, Antonio Daniele, et al.
Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery|October 15, 2011
Effect of botulinum toxin type A and modified constraint-induced movement therapy on motor function of upper limb in children with obstetrical brachial plexus palsyAndrea Santamato, Francesco Panza, Maurizio Ranieri, et al.
Ageing Research Reviews|August 28, 2019
Do anti-amyloid-β drugs affect neuropsychiatric status in Alzheimer's disease patients?Francesco Panza, Madia Lozupone, Antonello Bellomo, et al.
Expert Opinion on Pharmacotherapy|October 6, 2020
Pharmacological management of dementia with Lewy bodies with a focus on zonisamide for treating parkinsonismFrancesco Panza, Madia Lozupone, Mark Watling, et al.
Cellular and Molecular Life Sciences : CMLS|October 15, 2011
Metabolic syndrome as a risk factor for neurological disordersAkhlaq A Farooqui, Tahira Farooqui, Francesco Panza, et al.
Brain Research Bulletin|February 9, 2006
Nutritional factors, cognitive decline, and dementiaAngelo Del Parigi, Francesco Panza, Cristiano Capurso, et al.
Current Opinion in Psychiatry|January 22, 2014
Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?Francesco Panza, Giancarlo Logroscino, Bruno P Imbimbo, et al.
Expert Opinion on Investigational Drugs|July 14, 2020
Discontinued disease-modifying therapies for Alzheimer's disease: status and future perspectivesBruno P Imbimbo, Madia Lozupone, Mark Watling, et al.
Nature Reviews. Neurology|January 6, 2019
A critical appraisal of amyloid-β-targeting therapies for Alzheimer diseaseFrancesco Panza, Madia Lozupone, Giancarlo Logroscino, et al.
Expert Review of Neurotherapeutics|May 22, 2019
Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease?Francesco Panza, Madia Lozupone, Mark Watling, et al.
Pageof 41

Showing results (31-40 of 404) with videos related to

Sort By:
Pageof 41
Expert Opinion on Emerging Drugs|March 21, 2025
An update on emerging anti-amyloid-β monoclonal antibodies for treating Alzheimer's disease: the role of apolipoprotein EMadia Lozupone, Vittorio Dibello, Antonio Daniele, et al.
Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery|October 15, 2011
Effect of botulinum toxin type A and modified constraint-induced movement therapy on motor function of upper limb in children with obstetrical brachial plexus palsyAndrea Santamato, Francesco Panza, Maurizio Ranieri, et al.
Ageing Research Reviews|August 28, 2019
Do anti-amyloid-β drugs affect neuropsychiatric status in Alzheimer's disease patients?Francesco Panza, Madia Lozupone, Antonello Bellomo, et al.
Expert Opinion on Pharmacotherapy|October 6, 2020
Pharmacological management of dementia with Lewy bodies with a focus on zonisamide for treating parkinsonismFrancesco Panza, Madia Lozupone, Mark Watling, et al.
Cellular and Molecular Life Sciences : CMLS|October 15, 2011
Metabolic syndrome as a risk factor for neurological disordersAkhlaq A Farooqui, Tahira Farooqui, Francesco Panza, et al.
Brain Research Bulletin|February 9, 2006
Nutritional factors, cognitive decline, and dementiaAngelo Del Parigi, Francesco Panza, Cristiano Capurso, et al.
Current Opinion in Psychiatry|January 22, 2014
Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?Francesco Panza, Giancarlo Logroscino, Bruno P Imbimbo, et al.
Expert Opinion on Investigational Drugs|July 14, 2020
Discontinued disease-modifying therapies for Alzheimer's disease: status and future perspectivesBruno P Imbimbo, Madia Lozupone, Mark Watling, et al.
Nature Reviews. Neurology|January 6, 2019
A critical appraisal of amyloid-β-targeting therapies for Alzheimer diseaseFrancesco Panza, Madia Lozupone, Giancarlo Logroscino, et al.
Expert Review of Neurotherapeutics|May 22, 2019
Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease?Francesco Panza, Madia Lozupone, Mark Watling, et al.
Pageof 41